Previous Page Next Page
Section Table of Contents
Site Table of Contents
Medical Pharmacology Chapter 13:  Opioid Pharmacology Lecture, slide 2

press above to begin the lecture

 

 

Table of Contents: Opioids

  • Nomenclature

  • Opioids Definition

  • Source

  • Classification/Chemistry

    • Opioid Classification

    • Chemical Substitution

  • Endogenous Opioid Peptides

  • Pharmacokinetics

    • Absorption

    • Distribution

    • Metabolism

    • Excretion

  • Pharmacodynamics

    • Mechanism of Action

    • Receptor Binding

    • Receptor Types

    • General Opioid Receptor Properties

    • Opioid Receptor Subtypes: Table

    • Cellular Actions

      • G-Protein Links

      • Two well-defined Actions

      • Spinal Cord Sites of Action

        • Presynaptic Sites

    • Opioid Receptor Distribution

  • Systemic Opioid Administration

  • Tolerance and Physical Dependence

  • Opioid Effects: Degree of Tolerance Developed

Organ Systems

  • CNS

    • Analgesia

      • Spinal Cord

      • Supraspinal Sites of Action

      • Clinical Implications

    • Euphoria

    • Sedation

    •  Respiratory Depression

    • Cough Supression

    • Miosis

      • Clinical Implications

    • Truncal Rigidity

    • Nausea and Vomiting

  • Cardiovascular Effects

  • Gastrointestinal Effects

    • Constipation

  • Biliary Tract

  • Genitourinary Tract

  • Uterus

  • Neuroendocrine

  • Pentazocine  (Talwain)(and other)-- agonist-antagonists

  • Opioid Analgesics: Efficacy; Oral/Parenteral Potency Ratio

  • Summary of Opioid Analgesic Toxic Effects

Clinical Use: Opioid Analgesics

  • Analgesia

    • Obstetrical Labor

    • Renal/Biliary Colic

    • Acute Pulmonary Edema

    • Cough

    • Diarrhea

  • Opioids and Anesthesia

    • Anesthetic Premedication

    • Intraoperative Use-general

    • Intraoperative Use-regional

    • Other routes of Administration

  • Toxicity and Side Effects

    • Tolerance

    • Cross-Tolerance

    • Physiologic Dependence

    • Antagonist-Precipitated Withdrawal

    • Psychological Dependence

    • Prescribing Principles and Guidelines

    • Management/Treatment of Overdosage

    • Contraindications/Therapeutic Cautions

      • Pregnancy

      • Impaired Lung Function

      • Impaired Liver/Kidney Function

      • Endocrine Disorders

Specific Drugs

  • Strong Agonists

    • Phenanthrenes

      • Morphine

      • Hydromorphone

      • Oxymorphone (Numorphan)

    • Phenylheptylamines

      • Methadone (Dolophine)

        • pharmacodynamics

      • Levomethadyl acetate

    • Phenylpiperidines

      • Meperidine (Demerol)

      • Fentanyl Group

        • Fentanyl (Sublimaze)

        • Sufentanil  (Sufenta)

        • Alfentanil (Alfenta)

        • Remifentanil (Ultiva)

    • Morphinans: -- Levorphanol  (Levo-dromoran)

  • Mild/Moderate Agonists

    • Codeine, oxycodone (Roxicodone), dihydrocodeine, hydrocodone

    • Propoxyphene(Darvon)

    • Diphenoxylate (Lomotil)

    • Loperamide(Imodium)

  • Mixed Agonist-Antagonists & Partial Agonists

    • Nalbuphene

    • Buprenorphine (Buprenex)

    • Butorphanol

    • Pentazocine

    • Dezocine

  • Miscellaneous

    • Tramadol

  • Antitussives

  • Opioid Antagonists-Naloxone, Naltrexone, Nalmefene

    • Pharmacodynamics

    • Clinical Use

 

Pharmacodynamics

  • Mechanism of Action:

  • Receptor Types:

    • Mu (μ)

    • Delta (δ)

    • Kappa (κ)

    • General Opioid Receptor Characteristics:

      • G protein coupled receptor family

      • Significant amino acid sequence homology

      • Each-receptor: subtypes

        • μ1, μ2

        • δ1, δ2

        • κ1, κ2

    • Receptor types and physiological effects:

      • Mu (μ) :Analgesia, euphoria, respiratory depression, physiological dependence

      • Most opioid analgesics: act at the μ receptor

      • Delta (δ) and Kappa (k): Spinal analgesia

    • Drugs/endogenous opioids: Receptor- type affinity

      • Morphine -- (μ)

      • Pentazocine -- (κ) some (μ)

      • Endogenous opioid peptides:

        • Leu-enkephalin --(δ)

        • Dynorphin --(κ)

Opioid Receptor Subtype

Drug

Mu (m)

Delta (d)

Kappa (k)

Opioid Peptides

Enkephalins

Antagonist

Agonist

β-endorphin

Agonist

Agonist

Dynorphin

Weak Agonist

Agonist

Agonists

 

Codeine

Weak Agonist

Weak Agonist

Etorphine

Agonist

Agonist

Agonist

Fentanyl (Sublimaze)

Agonist

Meperidine (Demerol)

Agonist

Methadone (Dolophine)

Agonist

Morphine

Agonist

Weak Agonist

Agonist-antagonists

 

Buprenorphine

Partial Agonist

Dezocine (Dalgan)

Partial Agonist

Agonist

Nalbuphine (Nubain)

Antagonist

Agonist

Pentazocine (Talwain)

Antagonist or Partial Agonist

Agonist

Antagonist: naloxone (Narcan)

Antagonist

Antagonist

Antagonist

  • Cellular Action:

  • Spinal cord presynaptic sites:

    • Reduced transmitter released affecting acetylcholine, norepinephrine, glutamate, serotonin, substance P systems.

        • Serotonin, bradykinin, histamine, prostaglandins, substance P (sP) , and various ions (ie, H+ or K+), the biochemical mediators released as a result of tissue injury, have been implicated in nociceptive activation and sensitization (hyperalgesia).

        • Hyperalgesia results in enhancement of spontaneous pain via a reduction in pain threshold and a lengthening in duration of nociceptor response to stimuli.

        • PGE1, PGE2, and PGF2a, are the most potent prostaglandins to produce these sensitization effects.

        • Substance P, synthesized by cells of the spinal ganglia, has been identified at the peripheral terminal of unmyelinated primary afferent fibers.

          • This putative neurotransmitter may play a role in the propagation of visceral nociceptive pain from the gastrointestinal (GI) tract, ureters, and urinary bladder.

        •  In addition, to sP, other potential nociceptive transmitters include glutamate, aspartate, somatostatin, cholecystokinin, and vasoactive intestinal polypeptide.

        courtesy of Roxane Pain Institute used with permission

         

 

Way, W.L., Fields, H.L. and Way, E. L. Opioid Analgesics and Antagonists, in Basic and Clinical Pharmacology, (Katzung, B. G., ed) Appleton-Lange, 1998, pp 496-515.

Schuckit, M.A. and Segal D.S., Opioid Drug Abuse and Dependence, In Harrison's Principles of Internal Medicine 14th edition, (Isselbacher, K.J., Braunwald, E., Wilson, J.D., Martin, J.B., Fauci, A.S. and Kasper, D.L., eds) McGraw-Hill, Inc (Health Professions Division), 1998, pp 2508-2512.

Coda, B.A. Opioids, In Clinical Anesthesia, 3rd Edition (Barash, P.G., Cullen, B.F. and Stoelting, R.K.,eds) Lippincott-Ravin Publishers, Philadelphia, New York, 1997, pp 329-358.

 

  • Opioid Receptor Distribution

    • Spinal cord: dorsal horn

    • Primary afferents to pain transmission neurons

      • Opioid agonists:

        • Inhibit excitatory transmitters release from these primary afferents

        • Inhibit dorsal horn pain transmission neurons

        • Clinical application: directed administration of opioid agonists allow regional analgesia which minimizes CNS side effects

      • "C Fibers are small, unmyelinated nerves with slow conduction velocities that carry dull, aching burning pain impulses.

      • Thinly myelinated A afferent fibers carry fast, sharp, shooting pain sensations and are most integral to the propagation of mechanical pressure stimuli from muscles, joints, and bone.

      • Compared with these fibers, C afferent fibers have a higher threshold for mechanical stimuli and a smaller field of reception.

      • Both these classes of nociceptive fibers ultimately synapse with neurons in the dorsal horn of the spinal cord."

      courtesy of Roxane Pain Institute used with permission

       

 

  • Systemic Opioid Administration:

    • Action in both supraspinal and spinal sites

        • "Transmission of impulses, which as they reach consciousness will be interpreted as pain, begins with the activation of specific peripheral receptors called nociceptors by disease- or surgery-induced tissue injury.

        • Nociceptors usually respond to high intensity, potentially damaging stimuli.

          • Inflammatory processes often associated with disease or tissue trauma play a role in the initiation of nociception, mostly by sensitizing the nociceptors:

            • which causes lowering of their activation threshold.

          • Both A- and C-class nociceptors and their corresponding afferent fibers are the most important carriers of nociceptive stimuli from the skin, deep somatic structures, such as muscle and bone, and viscera.

          • On going nociceptor-evoked discharges carried by these afferent fibers enter the spinal cord via the dorsal roots, extending into several ascending nociceptive pathways.

          • The dorsal horn is not only a relay station for these signals, but also an area in which complex data integration of excitatory or inhibitory modulation occurs."

          courtesy of Roxane Pain Institute used with permission

         

    • Important opioid binding sites in descending pathways

      • Rostral ventral medulla

      • Locus ceruleus (see below)

      • Midbrain periaqueductal gray

    • Administration of exogenous opioids promotes release of endogenous opioids

    • Sagittal Brain View:  Anatomy Reference
      • Reticular formation (RF), vestibular nuclei (V), cerebellar roof nuclei (R), periaquiductal gray (PG).  Posterior hypothalamic nuclei (P), paraventricular hypothalamic nucleus (PV), substantia nigra (SN),  Thalamic nuclei (T), preoptic hypothalamic nuclei (PO), locus ceruleus (LC), median raphe nuclei (MR) . 

 

 

  • Tolerance/Physical Dependence

    • Repeated opioid administration results in a gradual loss of effect, e.g. tolerance

    • Physical Dependence = physiological withdrawal symptoms (abstinence syndrome) if an antagonist is administered or the agonist is stopped.

    • Tolerance is not developed equally to all opioid effects.

 

Opioid Effects: Degree of Tolerance Developed

High

Intermediate

Limited/None

Analgesia

Bradycardia

Miosis

Euphoria, dysphoria

 

Constipation

Mental clouding

 

Convulsions

 Sedation

 

Antagonist actions

Respiratory depression

   

Antidiuresis

   

Nausea/vomiting

   

Cough suppression

   

adapted from Figure 31-4: Way, W.L., Fields, H.L. and Way, E. L. Opioid Analgesics and Antagonists, in Basic and Clinical Pharmacology, (Katzung, B. G., ed) Appleton-Lange, 1998, p. 505.

 

 
 
 
 
Previous Page Next Page
Section Table of Contents
Site Table of Contents